List of Excipients in Branded Drug DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE

Generic Drugs Containing DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals of New York LLC	dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate	0115-1486	AMMONIA
Amneal Pharmaceuticals of New York LLC	dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate	0115-1486	FD&C BLUE NO. 1
Amneal Pharmaceuticals of New York LLC	dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate	0115-1486	FERRIC OXIDE RED
Amneal Pharmaceuticals of New York LLC	dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate	0115-1486	FERRIC OXIDE YELLOW

What are the Most Frequently-Used Excipients in DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE?

# Of NDCs	Excipient
5	AMMONIA
2	BUTYL ALCOHOL
1	CAPRYLIC/CAPRIC MONO/DI-GLYCERIDES
14	CELLULOSE, MICROCRYSTALLINE

Excipient Strategy and Commercial Opportunities for Mixed Amphetamine Salts

Last updated: August 6, 2026

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate are the four active pharmaceutical ingredients in mixed amphetamine salts products, including Adderall and Adderall XR. The main commercial opportunities are generic substitution, differentiated extended-release delivery, pediatric administration, dose flexibility, and supply-chain resilience.

Excipient selection is constrained by Schedule II controls, stimulant-related abuse concerns, bioequivalence requirements, taste and swallowability issues, and the pharmacokinetic sensitivity of immediate-release and extended-release products. The strongest opportunities are in robust immediate-release tablets, multiparticulate extended-release capsules, sprinkle formulations, and 505(b)(2) products with clinically meaningful administration or tolerability advantages.

What drug is protected by the mixed amphetamine salts formulation?

Mixed amphetamine salts contain four amphetamine salt forms with an overall predominance of dextroamphetamine activity. The product is commonly described as having a 3:1 ratio of dextroamphetamine to levoamphetamine base.

Component	Function in active blend
Dextroamphetamine saccharate	Dextroamphetamine source
Amphetamine aspartate monohydrate	Racemic amphetamine source
Dextroamphetamine sulfate	Dextroamphetamine source
Amphetamine sulfate	Racemic amphetamine source

The approved immediate-release product is administered as tablets. The extended-release product uses multiparticulate beads in capsules and is designed to provide an initial release phase followed by a delayed release phase. FDA labeling describes Adderall XR as a two-pulse delivery system with immediate-release and delayed-release components. [1]

The active ingredient is not a biologic, so biosimilar pathways do not apply. Competition proceeds primarily through ANDAs for generics or 505(b)(2) applications for modified delivery systems, new dosage forms, or other products that rely partly on FDA findings for an approved amphetamine product.

What excipients are used in immediate-release mixed amphetamine salts tablets?

Immediate-release tablets generally require a conventional solid-dose excipient system. FDA labeling identifies excipient classes including lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, starch-based materials, and tablet colorants, depending on strength and manufacturer. Exact composition varies by product and strength. [2]

Excipient class	Primary role	Commercial relevance
Lactose monohydrate	Diluent and tablet mass builder	Low-cost, established direct-compression or granulation option
Microcrystalline cellulose	Filler and dry binder	Supports compactability and mechanical strength
Starch or pregelatinized starch	Binder and disintegrant	Supports rapid breakup and manufacturability
Colloidal silicon dioxide	Glidant and moisture-control aid	Improves powder flow and blend uniformity
Magnesium stearate	Lubricant	Reduces sticking and ejection force
Colorants	Strength identification	Supports differentiation and medication-error control

The commercial objective for an immediate-release generic is usually not novel excipient chemistry. It is a reliable, low-cost composition that provides:

• rapid disintegration;
• consistent dissolution across strengths;
• low tablet weight;
• acceptable hardness and friability;
• blend uniformity for low-dose strengths;
• stable performance under humidity and temperature stress;
• visual differentiation across dose levels.

How should excipients be selected for low-dose amphetamine tablets?

Low-dose strengths create a blend-uniformity problem because the active load is small relative to the total tablet mass. Microcrystalline cellulose, spray-dried lactose, and a controlled starch system can improve content uniformity and compression performance. Over-lubrication with magnesium stearate can slow dissolution, particularly when blending time and lubricant surface area are not tightly controlled.

Silicon dioxide can improve flow but may increase dusting and segregation if used excessively. The formulation should be evaluated for segregation during hopper residence, transfer, and tablet compression rather than only at laboratory scale.

Colorant selection has a commercial role. Strength-specific colors help caregivers and pharmacists distinguish 5 mg, 10 mg, 20 mg, and other dose levels. Colorant changes may require additional comparative dissolution and stability work even when the active formulation remains unchanged.

What excipients are used in extended-release amphetamine capsules?

Extended-release products require a multiparticulate system rather than a conventional matrix tablet. The platform generally includes:

1. drug-loaded starter cores or pellets;
2. a drug-layering binder;
3. an immediate-release fraction;
4. a functional polymer coating for delayed release;
5. plasticizers and anti-tacking agents;
6. capsule-shell materials;
7. optional taste-masking or suspension aids.

FDA labeling identifies inactive ingredients in Adderall XR such as gelatin, hydroxypropyl methylcellulose, methacrylic acid copolymers, talc, sugar spheres, triethyl citrate, and dibutyl sebacate, with composition varying by product component. [3]

Formulation element	Typical excipient technology	Key performance risk
Starter core	Sugar spheres or microcrystalline cellulose pellets	Size distribution and drug-layer uniformity
Drug-layer binder	Hypromellose or povidone	Over-wetting, agglomeration, spray-rate sensitivity
Delayed-release coat	Methacrylic acid copolymer	pH-triggered release and coating integrity
Plasticizer	Triethyl citrate or similar material	Film flexibility and permeability
Anti-tacking agent	Talc	Coating efficiency and defect control
Capsule shell	Gelatin or hypromellose	Moisture transfer and shell compatibility
Suspension support	Cellulose derivatives or suspending agents	Required for sprinkle administration

The central technical challenge is controlling the timing and magnitude of the second release pulse. Small changes in polymer weight gain, coating porosity, plasticizer concentration, pellet size, or gastrointestinal pH exposure can change the pharmacokinetic profile.

What formulation patents protect mixed amphetamine salts products?

The principal protection for the original extended-release product was directed to the delivery architecture rather than to the basic amphetamine salts alone. Relevant patent categories include:

• multiparticulate bead systems;
• immediate-release and delayed-release bead populations;
• pH-dependent polymer coatings;
• dosing schedules that extend exposure across the day;
• capsule contents that may be administered by sprinkling;
• specific ratios of immediate-release to delayed-release drug;
• manufacturing methods for drug-layered pellets.

The Adderall XR patent estate historically included U.S. Patent No. 6,322,819 and related intellectual property associated with Shire, later part of Takeda. The original product has faced generic competition for more than a decade, and the commercial barrier is now primarily formulation execution, regulatory approval, supply reliability, and market access rather than broad exclusivity over amphetamine salts.

Patent coverage should be separated into four categories:

Protection type	Strategic value
Active-ingredient claims	Limited for long-established amphetamine salts
Formulation claims	Potentially important for bead architecture and release timing
Method-of-use claims	May cover ADHD or narcolepsy dosing, but enforcement depends on claim scope
Manufacturing claims	Can restrict specific coating or layering processes

A new developer should conduct a current claim chart against issued patents, continuations, terminal disclaimers, Orange Book listings, and FDA patent certifications before selecting a platform. Patent expiration dates cannot be inferred solely from the approval date because patent term adjustment, pediatric exclusivity, disclaimers, and continuation practice may alter the effective date.

When does mixed amphetamine salts lose exclusivity?

The product has already lost core market exclusivity for immediate-release amphetamine tablets. Generic immediate-release products are approved through the ANDA pathway.

Extended-release competition also exists. FDA has approved generic versions of mixed amphetamine salts extended-release capsules, including products from multiple manufacturers. The relevant barriers are therefore product-specific:

Product category	Primary regulatory route	Competitive status
Immediate-release tablets	ANDA	Mature generic market
Extended-release capsules	ANDA with complex bioequivalence requirements	Competitive but technically more difficult
New modified-release capsule	505(b)(2) or ANDA, depending on sameness	Opportunity for differentiated delivery
Orally disintegrating tablet	Usually 505(b)(2) if clinically or formulationally distinct	Potential administration advantage
Liquid or suspension	505(b)(2) or ANDA if pharmaceutically equivalent	Pediatric and swallowing opportunity
Abuse-deterrent product	505(b)(2) or ANDA depending on formulation	Higher development and evidence burden

FDA Orange Book listings remain the governing source for listed patents, exclusivity, dosage forms, and reference products. [4] A patent that is expired, delisted, or not applicable to the proposed product does not necessarily remove all formulation or litigation risk.

What Paragraph IV challenges affect mixed amphetamine salts?

Paragraph IV certifications are most relevant to extended-release products with listed formulation or delivery patents. An ANDA applicant may certify that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed. The filing can trigger patent litigation under the Hatch-Waxman Act.

For a generic applicant, the commercial questions are:

• Is the listed patent still enforceable at the expected launch date?
• Does the proposed bead system fall within the asserted claims?
• Does the applicant need a Paragraph IV certification or a Paragraph III certification?
• Is a 30-month stay possible?
• Does the first substantially complete ANDA qualify for 180-day exclusivity?
• Are there settlement restrictions affecting launch timing?

Historical litigation around Adderall XR centered on generic extended-release products and the scope of patent claims covering controlled-release bead systems. The immediate-release tablet market has fewer formulation barriers because conventional tablets are easier to match and have been commercially generic for many years.

How strong is the patent estate for a new mixed amphetamine salts formulation?

The patent estate is strongest when the product has a measurable delivery or administration difference that cannot be easily designed around. A patent strategy based only on substituting one conventional diluent for another is weak because excipient selection may be obvious and difficult to defend.

Stronger patent positions

• A defined two-pulse or multi-pulse pharmacokinetic profile.
• A novel polymer-coating architecture that produces a reproducible delay.
• A sprinkle formulation with demonstrated stability and dose recovery.
• A low-dose formulation with improved content uniformity and reduced tablet burden.
• A formulation with reduced food effect.
• A product with clinically demonstrated abuse-deterrent performance.
• A stable liquid or suspension that solves pediatric administration problems.

Weaker patent positions

• Routine substitution of lactose with mannitol.
• Standard use of microcrystalline cellulose and magnesium stearate.
• Unclaimed colorant changes.
• Conventional gelatin or hypromellose capsule shells.
• Broad claims covering known amphetamine salt combinations.
• Dissolution differences that are not linked to a clinically meaningful advantage.

Patent claims should include composition, dosage form, release profile, manufacturing process, and use claims where supported by the development data. The strongest portfolio usually combines formulation claims with manufacturing claims because process know-how can be difficult for competitors to replicate even when the composition is public.

What FDA regulatory requirements apply to excipient strategy?

The active ingredient is well established, but each product still requires control of quality, performance, and bioequivalence. FDA’s Inactive Ingredient Database can support excipient selection by showing prior use levels and routes of administration. [5]

Key regulatory requirements include:

• identity and assay of each amphetamine salt;
• control of individual amphetamine isomers;
• content uniformity across strengths;
• dissolution testing under discriminating conditions;
• impurity and degradation-product controls;
• extractables and leachables assessment for coated beads and capsule shells;
• stability under ICH conditions;
• comparative pharmacokinetics for extended-release products;
• food-effect evaluation where relevant;
• alcohol-dose-dumping assessment for modified-release products;
• container-closure protection from moisture and light.

For a conventional ANDA, the formulation should be pharmaceutically equivalent to the reference product and bioequivalent under FDA standards. A formulation with a new release mechanism, new administration route, or meaningful clinical differentiation may require a 505(b)(2) application.

Schedule II status imposes additional operational requirements. Manufacturing, packaging, inventory, returns, destruction, forecasting, and distribution must comply with Drug Enforcement Administration controls. The excipient strategy cannot compensate for shortages caused by active pharmaceutical ingredient quotas or controlled-substance distribution limits.

What commercial opportunities exist for amphetamine excipient platforms?

Generic immediate-release tablets

The immediate-release segment is price competitive, but manufacturing efficiency and supply reliability remain valuable. Opportunities include:

• low-cost direct-compression platforms;
• fewer excipient suppliers;
• common granulation processes across strengths;
• reduced tablet weight;
• improved friability during high-speed compression;
• packaging that reduces pharmacy handling and product loss.

The principal risk is limited differentiation. A new entrant needs a low-cost manufacturing position, reliable API access, or a strong channel strategy.

Extended-release multiparticulates

Extended-release capsules have greater technical value because coating uniformity and dissolution performance create meaningful development barriers. A developer can compete through:

• lower variability in the second release pulse;
• lower food sensitivity;
• improved stability under humidity;
• lower capsule fill weight;
• more efficient coating yield;
• a controlled immediate-release-to-delayed-release ratio;
• improved sprinkle recovery.

Sprinkle and pediatric products

Pediatric administration is one of the clearest commercial opportunities. A capsule that can be opened and sprinkled on soft food must preserve dose uniformity, release performance, palatability, and stability after administration.

Excipient priorities include:

• low-grit bead surfaces;
• effective taste masking;
• low moisture uptake;
• minimal interaction with acidic or neutral foods;
• rapid recovery of the intended release profile;
• low risk of bead adhesion to utensils or food containers.

A pediatric formulation can support a 505(b)(2) strategy if it provides a clinically relevant administration advantage not available in the reference product.

Orally disintegrating and liquid products

An orally disintegrating tablet could address patients who cannot swallow capsules or tablets. The formulation must manage the bitter taste of amphetamine and avoid excessive friability.

A liquid or suspension could expand use in younger patients, but it introduces:

• preservative compatibility;
• dose-measurement accuracy;
• chemical and microbiological stability;
• container dosing-device requirements;
• controlled-substance handling risks;
• taste-masking requirements.

The product must demonstrate that excipients do not materially alter amphetamine absorption or dose delivery.

Abuse-deterrent and tamper-resistant systems

Abuse-deterrent products may have commercial value, but the evidence burden is substantially higher than for a conventional generic. Candidate approaches include:

• increased resistance to crushing;
• polymer matrices that resist extraction;
• aversive excipients;
• reduced ability to convert the dosage form into an injectable or insufflatable product;
• controlled-release systems that resist dose dumping.

FDA’s abuse-deterrence guidance distinguishes laboratory manipulation studies from pharmacokinetic and clinical abuse-potential evidence. [6] A product should not make abuse-deterrent claims without data meeting the applicable FDA framework.

How does mixed amphetamine salts compare with competing ADHD stimulants?

Product class	Dosage-form opportunity	Excipient and formulation challenge
Mixed amphetamine salts IR	Conventional tablet	Low differentiation and price pressure
Mixed amphetamine salts XR	Coated multiparticulates	Release-pulse control and bioequivalence
Lisdexamfetamine	Prodrug capsule, chewable	Prodrug-specific pharmacology and formulation
Methylphenidate ER	Matrix, osmotic, or multiparticulate systems	Broad competitive field and complex release technologies
Dextroamphetamine ER	Extended-release capsule or tablet	Narrow active-ingredient positioning
Nonstimulant ADHD products	Tablet, capsule, liquid	Different mechanism and longer titration profile

Mixed amphetamine salts have a broad prescriber base and established clinical use, but they face competition from methylphenidate products, lisdexamfetamine, atomoxetine, guanfacine, and other ADHD therapies. A new product must offer an advantage in duration, tolerability, administration, abuse resistance, or access.

What manufacturing and intellectual-property barriers matter most?

The principal manufacturing barrier for extended-release products is consistent bead coating at commercial scale. Critical process parameters include:

• starter-core size distribution;
• drug-layer spray rate;
• inlet and product temperature;
• atomization pressure;
• coating weight gain;
• polymer-to-plasticizer ratio;
• curing time;
• capsule fill accuracy;
• segregation control.

Manufacturing know-how may create a practical barrier even where patent protection is limited. A product can fail commercial launch because of dissolution drift, coating defects, capsule-shell moisture transfer, or inadequate supply of functional polymers.

The most defensible strategy is to develop a platform with multiple formulation embodiments and a process that can be transferred between qualified manufacturing sites. Functional excipients should have at least two qualified suppliers where possible. A single-source polymer, capsule shell, or coating additive can create a greater business risk than a narrow patent claim.

What generic launch risks exist for mixed amphetamine salts?

Generic launch risk is driven by five factors:

1. Patent and certification timing.
2. FDA review of complex-release bioequivalence.
3. Controlled-substance API availability.
4. Manufacturing capacity and quota allocation.
5. Wholesale and pharmacy substitution dynamics.

For immediate-release tablets, regulatory and patent risk is lower, but price erosion is higher. For extended-release capsules, development risk is higher, while a reliable product with consistent supply can capture share during shortages or manufacturer withdrawals.

A launch plan should include strength-by-strength manufacturing capacity, multiple API and excipient suppliers, serialized packaging where required, and a documented response to FDA shortage conditions. Supply continuity is commercially important in a market where pharmacy substitution can shift quickly among approved suppliers.

What is the outlook for excipient suppliers and formulation licensors?

Excipient suppliers can capture value through functional systems rather than commodity materials. The most attractive offerings include:

• ready-to-use pellet cores;
• optimized enteric coating systems;
• taste-masking platforms;
• low-moisture capsule shells;
• directly compressible blends;
• abuse-deterrent polymer systems;
• formulation-development packages with dissolution and scale-up data.

Licensing opportunities are strongest when the licensor owns a validated multiparticulate platform, demonstrated bioequivalence data, or manufacturing know-how that shortens ANDA development. A generic company may prefer a license to a proven bead-coating process over a license to a broad but unvalidated composition patent.

Key Takeaways

• Mixed amphetamine salts are the active ingredients in Adderall and Adderall XR, with a formulation commonly described as having a 3:1 dextroamphetamine-to-levoamphetamine base ratio.
• Immediate-release tablets are mature generic products with limited formulation differentiation.
• Extended-release capsules offer greater commercial opportunity because multiparticulate coating and release control are technically demanding.
• The most relevant excipients include lactose, microcrystalline cellulose, starch, colloidal silicon dioxide, magnesium stearate, gelatin or hypromellose capsules, methacrylic acid copolymers, talc, and plasticizers.
• Pediatric sprinkle, orally disintegrating, liquid, and abuse-deterrent products offer potential 505(b)(2) opportunities.
• The strongest patent positions cover release architecture, administration advantages, manufacturing processes, or demonstrated pharmacokinetic improvements.
• FDA Orange Book review, Paragraph IV analysis, controlled-substance supply planning, and commercial-scale coating capability are required before investment.
• Excipient suppliers can create value through validated functional systems, particularly multiparticulate coating and taste-masking platforms.

FAQs

Can lactose-free mixed amphetamine salts tablets be commercially differentiated?

Yes, but lactose removal alone is usually a weak differentiation strategy. A lactose-free product may support a formulation or 505(b)(2) program if it addresses a documented intolerance or administration issue and maintains equivalent performance.

Can mixed amphetamine salts be formulated as an oral suspension?

Yes. A suspension would require control of dose uniformity, sedimentation, redispersibility, preservative performance, chemical stability, and taste. Regulatory requirements depend on whether the product is pharmaceutically equivalent to an approved reference product.

Which excipient creates the greatest risk in extended-release amphetamine products?

The functional delayed-release coating is usually the highest-risk excipient system. Polymer grade, particle size, plasticizer level, coating weight gain, curing, and pH-dependent permeability directly affect the second release phase.

Is a new capsule shell enough to obtain patent protection?

Usually not. A new capsule shell must provide a non-obvious, measurable benefit such as improved moisture protection, modified release, reduced interaction with pellet coatings, or enhanced administration performance.

Can an excipient platform be licensed to multiple generic manufacturers?

Yes, subject to exclusivity, patent scope, confidentiality, manufacturing capacity, and regulatory ownership terms. A platform license is more commercially defensible when it includes validated process parameters, comparative dissolution data, and scale-up support.

References

1. U.S. Food and Drug Administration. (2023). Adderall XR prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/

2. U.S. Food and Drug Administration. (2023). Adderall tablets prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/

3. U.S. Food and Drug Administration. (2023). Adderall XR inactive ingredients and dosage-form information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/

6. U.S. Food and Drug Administration. (2015). Guidance for industry: Abuse-deterrent opioids: Evaluation and labeling. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/abuse-deterrent-opioids-evaluation-and-labeling